Showing 6511-6520 of 7666 results for "".
Support for Population- Based Skin Cancer Screenings
https://practicaldermatology.com/topics/skin-cancer-photoprotection/support-for-population--based-skin-cancer-screenings/21675/A new study offers data to show that general skin cancer screenings by dermatologists and properly trained physicians can reduce morbidity and mortality.Sunscreen Labeling
https://practicaldermatology.com/topics/practice-management/sunscreen-labeling-/19370/Neal Bhatia, MD discusses the impact of new sunscreen labeling on patient education, as well as strategies for UV avoidance, and trends in therapeutic development.Body Contouring
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/body-contouring/19413/Dr. Amy Derick discusses the latest way to achieve a leaner, more sculpted look with CoolSculpting® by Zeltiq®.How Physicians Can Use the New AD Guidelines in Practice
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/how-physicians-can-use-the-new-ad-guidelines-in-practice/24094/In this second part of the inaugural edition of Practical Dermatology's® Atopic Dermatitis (AD) Journal Club, Derek Chu, MD, a key architect of new guidelines for AD management and care, talks with Peter Lio, MD, about his vision for how to make these guidelines easy-to-use and practical for dermatoAtopic Dermatitis and Psoriasis: Treatments, Considerations, and What’s Coming
https://practicaldermatology.com/programs/practical-dermatology/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/Atopic dermatitis (AD) and plaque psoriasis (PsO) are two of the most common cutaneous conditions we treat in dermatology. While these chronic inflammatory disorders have similarities, regarding chronic skin disease burden and impact on quality of life, they may diverge when considering clinical prePsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Dispatches from the 2022 Skin of Color Update
https://practicaldermatology.com/conferences/skin-of-color-update-2022/dispatches-from-the-2022-skin-of-color-update/23822/Co-chair Dr. Andrew F. Alexis shares highlights from the recent meeting.Success Factors in Selling A Dermatology Practice
https://practicaldermatology.com/topics/practice-management/success-factors-in-selling-a-dermatology-practice/23499/What to do if you’re considering a sale or merger.Reclaiming “Quality” in Dermatology
https://practicaldermatology.com/topics/practice-management/reclaiming-quality-in-dermatology/23432/Dermatologists know quality care when they see it. It’s time to take an active role in defining meaningful quality measures.“No-touch” Surgical Excision & “Double-freeze-thaw” Cryotherapy Techniques
https://practicaldermatology.com/topics/skin-cancer-photoprotection/conjunctival-scc/19861/A 68-year-old white male with a history of basal cell carcinoma of the right lower eyelid, surgically excised 10 years prior to presentation, was referred to the Ocular Oncology Service at Wills Eye Hospital, Philadelphia for an asymptomatic conjunctival lesion on the right eye. The patient was trea